Oncology patients undergoing chemotherapy often present with associated renal dysfunction requiring dosage modifications due to possible accumulation of toxic metabolites. We have devised a chart which can be used as a guideline by the physician for determining dosage modifications of cancer chemotherapeutic agents in patients with renal failure.
Get full access to this article
View all access options for this article.
References
1.
AdamsonR. H.AgneS. L.: The Distribution of Excretion and Metabolism of Hydroxyurea-C14, J. Pharmacol. Exper. Ther.150: 322, 1965.
2.
American Society of Hospital Pharmacists: American Hospital Formulary Service, p. 10: 00.
3.
AviadoD. M.: In, Krantz and Carr's Pharmacological Principles of Medical Practice, 8th Edition, Williams and Wilkins Co., Baltimore, 1972. p. 970.
4.
BaileyGeorge L.: Hemodialysis — Principles and Practice, Academic Press, 1972, p. 162–165.
5.
BenjaminR. S.: Pharmacokinetics and Metabolism of Adriamycin in Man, Clin. Pharmacol. Ther.14: 592–599, 1975.
6.
BennettW. M.: A Guide to Drug Therapy in Renal Failure, J. Am. Med. Assoc.230: 1544–1553, 1974.
7.
BennettWilliam M.: Guide to Drug Usage in Adult Patients With Impaired Renal Function, J. Am. Med. Assoc.223: 991–997 (Feb. 26) 1973.
8.
ChabnerBruce A.: The Clinical Pharmacology of Antineoplastic Agents, New Engl. J. Med.292: 1159–1167, 1975.
9.
DiPalmaJ. R.: Drill's Pharmacology in Medicine, 8th Edition, McGraw Hill Book Co., 1971, p. 1599.
10.
FujitaH.: Comparative Studies in The Blood Level, Tissue Distribution, Excretion and Inactivation of Anticancer Drugs, Jap. J. Clin. Oncol.12: 151, 1971.
11.
GoodmanLouis S.GilmanAlfred: The Pharmacological Basis of Therapeutics, 5th Edition, MacMillan Publishing Co., New York, 1975, p. 1377, 1380.
12.
HendersonEdwardAdamsonRichard: The Metabolic Fate of Tritiated Methotrexate, II. Absorption and Excretion in Man, Cancer Research25: 1018–1023 (Aug.) 1965.
13.
HollandJames F.FreiEmil: Cancer Medicine, Lea and Febiger, Philadelphia, p. 844, 1973.
14.
LeechS. H.: Chronic Hemodialysis in Myelomatosis, Ann. Intern. Med.77: 239–242, 1972.
15.
LePageG. A.WhitecanJ. P.: Pharmacology of 6-Tuioguarine in Man, Cancer Research31: 1627–1631 (Nov.) 1971.
16.
LevinD. H.: The Fate of Doubly-Labeled Radioactive Thiotepa Following Intravenous Administration and in Combination with Peritoneal Dialysis in Patients with Advanced Metastatic Ovarian Cancer, Obstet Gynecol27: 598–599, 1966.
17.
LiuK.: Renal Toxicity in Man Treated with Mitomycin C, Ann. Intern. Med.77: 239–242, 1972.
18.
MelletL. B.: Absorption and Fate of C14-Labelled N-N1, N11-Triethylenethiophosphoramide (Thio-Tepa) in Humans and Dogs, J. Lab. Clin. Med.60: 818–825, 1962.
19.
MouridsenH. T.: Pharmacokinetics of Cyclophosphamide in Renal Failure, Acta Pharmacol. Toxicol.36: 409–414, 1975.
20.
OliverioVincent: Some Pharmacologic Properties of a New Antitumor Agent, N-Isopropye-a-(2-Methylhydrazine) -p-Tohiamide Hydrochloride, Cancer, Chemotherapy Reports, No. 42 (Nov.) 1964.
21.
PittilloR. F.WoolleyC.RiceL. S.: Bleomycin and Antitumor Antibiotic: Improved Microbiological Assay and Tissue Distribution Studies in Normal Mice, Appl. Microbiol.2: 564–566, 1971.
22.
Professional Product Information: Medical Services Dept.
23.
ReidenburgM. M.: Renal Function and Drug Action, W. B. Saunders Company, Philadelphia, 1971.
24.
SchellhammerP. F.: Renal Failure Associated With the Use of Thio-Tepa, J. Urol.110: 498–501, 1973.
25.
SpivackS. D.: Procarbazine, Ann. Intern. Med.81: 795–800, 1974.
26.
TorkelsonA. R.: The Metabolic Fate of Cyclophosphamide, Drug Metabolism Reviews3: 131–165, 1974.
27.
UmezawaH.: Studies on Bleomycin Cancer, 20: 91–5, 1967.
